Literature DB >> 34555665

Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma.

Gayathri Ravi1, Wilson I Gonsalves2.   

Abstract

Entities:  

Keywords:  Diagnosis; Multiple myeloma; Prognosis; Treatment

Mesh：

Year:  2021        PMID： 34555665      PMCID： PMC8688330          DOI： 10.1016/j.ctarc.2021.100444

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN： 2468-2942


× No keyword cloud information.
  64 in total

Review 1.  Multiple myeloma epidemiology and survival: A unique malignancy.

Authors:  Dickran Kazandjian
Journal:  Semin Oncol       Date:  2016-11-10       Impact factor: 4.929

2.  Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Authors:  Thierry Facon; Shaji Kumar; Torben Plesner; Robert Z Orlowski; Philippe Moreau; Nizar Bahlis; Supratik Basu; Hareth Nahi; Cyrille Hulin; Hang Quach; Hartmut Goldschmidt; Michael O'Dwyer; Aurore Perrot; Christopher P Venner; Katja Weisel; Joseph R Mace; Noopur Raje; Michel Attal; Mourad Tiab; Margaret Macro; Laurent Frenzel; Xavier Leleu; Tahamtan Ahmadi; Christopher Chiu; Jianping Wang; Rian Van Rampelbergh; Clarissa M Uhlar; Rachel Kobos; Ming Qi; Saad Z Usmani
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

3.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

Authors:  Ruben Niesvizky; Ian W Flinn; Robert Rifkin; Nashat Gabrail; Veena Charu; Billy Clowney; James Essell; Yousuf Gaffar; Thomas Warr; Rachel Neuwirth; Yanyan Zhu; Jennifer Elliott; Dixie-Lee Esseltine; Liviu Niculescu; James Reeves
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

4.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Authors:  Nikhil C Munshi; Kenneth C Anderson; P Leif Bergsagel; John Shaughnessy; Antonio Palumbo; Brian Durie; Rafael Fonseca; A Keith Stewart; Jean-Luc Harousseau; Meletios Dimopoulos; Sundar Jagannath; Roman Hajek; Orhan Sezer; Robert Kyle; Pieter Sonneveld; Michele Cavo; S Vincent Rajkumar; Jesus San Miguel; John Crowley; Hervé Avet-Loiseau
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Authors:  Meletios A Dimopoulos; Francesca Gay; Fredrik Schjesvold; Meral Beksac; Roman Hajek; Katja Christina Weisel; Hartmut Goldschmidt; Vladimir Maisnar; Philippe Moreau; Chang Ki Min; Agnieszka Pluta; Wee-Joo Chng; Martin Kaiser; Sonja Zweegman; Maria-Victoria Mateos; Andrew Spencer; Shinsuke Iida; Gareth Morgan; Kaveri Suryanarayan; Zhaoyang Teng; Tomas Skacel; Antonio Palumbo; Ajeeta B Dash; Neeraj Gupta; Richard Labotka; S Vincent Rajkumar
Journal:  Lancet       Date:  2018-12-10       Impact factor: 79.321

6.  Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

Authors:  Francesca Gay; Stefania Oliva; Maria Teresa Petrucci; Concetta Conticello; Lucio Catalano; Paolo Corradini; Agostina Siniscalchi; Valeria Magarotto; Luděk Pour; Angelo Carella; Alessandra Malfitano; Daniela Petrò; Andrea Evangelista; Stefano Spada; Norbert Pescosta; Paola Omedè; Philip Campbell; Anna Marina Liberati; Massimo Offidani; Roberto Ria; Stefano Pulini; Francesca Patriarca; Roman Hajek; Andrew Spencer; Mario Boccadoro; Antonio Palumbo
Journal:  Lancet Oncol       Date:  2015-11-17       Impact factor: 41.316

Review 7.  How we manage autologous stem cell transplantation for patients with multiple myeloma.

Authors:  Morie A Gertz; David Dingli
Journal:  Blood       Date:  2014-06-27       Impact factor: 22.113

8.  Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma.

Authors:  Aaron S Rosenberg; Ann Brunson; Brian A Jonas; Theresa H M Keegan; Ted Wun
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

9.  Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Authors:  H Goldschmidt; H M Lokhorst; E K Mai; B van der Holt; I W Blau; S Zweegman; K C Weisel; E Vellenga; M Pfreundschuh; M J Kersten; C Scheid; S Croockewit; R Raymakers; D Hose; A Potamianou; A Jauch; J Hillengass; M Stevens-Kroef; M S Raab; A Broijl; H W Lindemann; G M J Bos; P Brossart; M van Marwijk Kooy; P Ypma; U Duehrsen; R M Schaafsma; U Bertsch; T Hielscher; Le Jarari; H J Salwender; P Sonneveld
Journal:  Leukemia       Date:  2017-07-04       Impact factor: 11.528

10.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.